Wilson Disease Drugs Market By Drug Type (Penicillamine, Trientine, Zinc), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Wilson Disease Drugs Market

Wilson disease is an inherited disorder in which excessive amounts of copper accumulate in the body, particularly in the liver, brain, and eyes. The signs and symptoms of Wilson disease usually first appear between the ages of 5 and 38, but they most often begin during the teenage years. The features of this condition include a combination of liver disease and neurological and psychiatric problems.

Liver disease is typically the initial feature of Wilson disease in affected children and young adults; individuals diagnosed at an older age usually do not have symptoms of liver problems, although they may have very mild liver disease. The signs and symptoms of liver disease include yellowing of the skin or whites of the eyes (jaundice), fatigue, loss of appetite, and abdominal swelling.

Nervous system or psychiatric problems are often the initial features in individuals diagnosed in adulthood and commonly occur in young adults with Wilson disease. Signs and symptoms of these problems can include clumsiness, tremors, difficulty walking, speech problems, impaired thinking ability, depression, anxiety, and mood swings. In many individuals with Wilson disease, copper deposits in the front surface of the eye (The cornea) form a green-to-brownish ring, called the Kayser-Fleischer ring, that surrounds the colored part of the eye. Abnormalities in eye movements, such as a restricted ability to gaze upwards, may also occur.

The key factors that drive the growth of wilson disease drugs market size is increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. Moreover, increase in investmentby players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure are further expected to boost the wilson disease drugs industry growth during forecast period. However, high treatment cost due to complications is likely to hamper the growth of the Wilson disease drugs market during the forecast period. Conversely, high investment by the government for drug development and increase in healthcare expenditure are expected to provide numerous opportunities for market growth during the forecast period.

By drug type, the Penicillamine segment dominated the wilson disease drugs market share in 2021 and is expected to remain dominant during the forecast period, owing to increase in prevalence of Wilson disease. In addition, penicillamine binds to copper and helps it to be removed from the body. Decreasing copper levels helps to improve liver function and the mental/mood/nerve problems (such as confusion, difficulty speaking/walking) caused by the disease further boost the wilson disease drugs market trends.

By distribution channel, the retail pharmacies segment dominated the wilson disease drugs market share in 2021 and is expected to remain dominant during the forecast period, owing to increase in Wilson disease patients, the growing number of independent pharmacies and chains along with the availability of medications in supermarkets & mass retailers in countries, such as the U.S. and UK. In addition, the presence of large chains, such as CVS Health, Boots Walgreens, Shoppers Drug Mart, Lloyd, and Well pharmacy, in a few countries, such as the U.S., Canada, the U.K., Australia, and Russia Further propel the market growth. Moreover, the rapid adoption of automation technologies, such as pharmacy robots, dispensing, and packaging systems is driving the segment growth.

Region wise, wilson disease drugs market analysis across North America, Europe, asia-Pacific and LAMEA. North America has the highest market share, with $251.28 million in 2021, registering a CAGR of 2.2% during the forecast period. Owing to the investments  made by the key players for various R&D activities as well as launch of new products in the U.S. In addition, increase awareness among the consumers for the adoption of Wilson disease drugs is further anticipated to stimulate the growth of the Wilson disease drugs industry in North America. Asia pacific is projected to register the highest CAGR of 5.5% during the wilson disease drugs market forecast period. The evolving healthcare regulatory landscape, an increase in the number of patients with Wilson diseases, and the government's emphasis on enhancing R&D capabilities for innovative drug development are the key driving factors that boost the growth of the market in the region.

Key findings of the study

• On the basis of drug type, the penicillamine segment dominated the market in 2021 and is expected to continue this trend during the forecast period.

• Depending on distribution channel, retail pharmacies segment is projected to grow at a CAGR of 2.2% during the forecast period.

• Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 5.5% during the forecast period.

Overview

The global Wilson disease drugs market accounted for $595.17 million in 2021, and is expected to reach $848.19 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.

Wilson disease is a rare inherited disorder that causes copper to accumulate in the liver, brain and other vital organs of human body. most people with Wilson's disease are diagnosed between the ages of 5 and 35, but it can affect younger and older people, as well. Copper plays a key role in the development of healthy nerves, bones, collagen and the skin pigment melanin. It is normally absorbed from food, and excess is excreted through a substance produced in liver (bile). However, in people with Wilson's disease, copper is not eliminated properly and instead accumulates, possibly to a life-threatening level. Wilson's disease is treatable when diagnosed early, and many people with the disorder live normal lives.

Wilson's disease is inherited as an autosomal recessive trait, this indicates that a person must inherit one copy of the defective gene from each parent in order to have the disease. If the person receives only one abnormal gene, he may not become ill himself, but he is a carrier and can pass the gene to children. Untreated Wilson's disease can be fatal. Serious complications include scaring of liver, kidney problems, liver failure, persistent neurological problems, psychological problems, and blood problems. Wilson disease drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine which further facilitate the growth of the market. However, lack of awareness and diagnosis facility associated with Wilson disease treatment and high treatment cost due to complications are expected to impede the market growth. In contrast, high investment by the government for drug development and increase in healthcare expenditure are factors that present new pathway in the industry are anticipated to provide significant growth opportunities for the Wilson disease drugs market.

The Wilson disease drugs market is segmented on the basis of drug type, distribution channel and region. Depending on drug type, the market is classified into Penicillamine, Trientine and Zinc. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global Wilson disease drugs market. The key companies profiled in the report include ANI Pharmaceuticals, Inc., APOTEX, Bausch Health Companies Inc., Breckenridge Pharmaceutical, Inc., Dr. Reddy's Laboratories Ltd, Lupin Limited, NAVINTA LLC, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vivet Therapeutics

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wilson disease drugs market analysis from 2021 to 2031 to identify the prevailing wilson disease drugs market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the wilson disease drugs market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global wilson disease drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ breckenridge pharmaceutical, inc

Scope of Wilson Disease Drugs Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Market dynamics

3.4.1.Drivers

3.4.2.Restraints

3.4.3.Opportunities

3.5.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Penicillamine

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3 Trientine

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

4.4 Zinc

4.4.1 Key market trends, growth factors and opportunities

4.4.2 Market size and forecast, by region

4.4.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Retail Pharmacies

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 Hospital Pharmacies

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

5.4 Online Pharmacies

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 North America

6.2.1 Key trends and opportunities

6.2.2 North America Market size and forecast, by Drug Type

6.2.3 North America Market size and forecast, by Distribution Channel

6.2.4 North America Market size and forecast, by country

6.2.4.1 U.S.

6.2.4.1.1 Key market trends, growth factors and opportunities

6.2.4.1.2 Market size and forecast, by Drug Type

6.2.4.1.3 Market size and forecast, by Distribution Channel

6.2.4.2 Canada

6.2.4.2.1 Key market trends, growth factors and opportunities

6.2.4.2.2 Market size and forecast, by Drug Type

6.2.4.2.3 Market size and forecast, by Distribution Channel

6.2.4.3 Mexico

6.2.4.3.1 Key market trends, growth factors and opportunities

6.2.4.3.2 Market size and forecast, by Drug Type

6.2.4.3.3 Market size and forecast, by Distribution Channel

6.3 Europe

6.3.1 Key trends and opportunities

6.3.2 Europe Market size and forecast, by Drug Type

6.3.3 Europe Market size and forecast, by Distribution Channel

6.3.4 Europe Market size and forecast, by country

6.3.4.1 Germany

6.3.4.1.1 Key market trends, growth factors and opportunities

6.3.4.1.2 Market size and forecast, by Drug Type

6.3.4.1.3 Market size and forecast, by Distribution Channel

6.3.4.2 France

6.3.4.2.1 Key market trends, growth factors and opportunities

6.3.4.2.2 Market size and forecast, by Drug Type

6.3.4.2.3 Market size and forecast, by Distribution Channel

6.3.4.3 UK

6.3.4.3.1 Key market trends, growth factors and opportunities

6.3.4.3.2 Market size and forecast, by Drug Type

6.3.4.3.3 Market size and forecast, by Distribution Channel

6.3.4.4 Italy

6.3.4.4.1 Key market trends, growth factors and opportunities

6.3.4.4.2 Market size and forecast, by Drug Type

6.3.4.4.3 Market size and forecast, by Distribution Channel

6.3.4.5 Spain

6.3.4.5.1 Key market trends, growth factors and opportunities

6.3.4.5.2 Market size and forecast, by Drug Type

6.3.4.5.3 Market size and forecast, by Distribution Channel

6.3.4.6 Rest of Europe

6.3.4.6.1 Key market trends, growth factors and opportunities

6.3.4.6.2 Market size and forecast, by Drug Type

6.3.4.6.3 Market size and forecast, by Distribution Channel

6.4 Asia-Pacific

6.4.1 Key trends and opportunities

6.4.2 Asia-Pacific Market size and forecast, by Drug Type

6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel

6.4.4 Asia-Pacific Market size and forecast, by country

6.4.4.1 China

6.4.4.1.1 Key market trends, growth factors and opportunities

6.4.4.1.2 Market size and forecast, by Drug Type

6.4.4.1.3 Market size and forecast, by Distribution Channel

6.4.4.2 Japan

6.4.4.2.1 Key market trends, growth factors and opportunities

6.4.4.2.2 Market size and forecast, by Drug Type

6.4.4.2.3 Market size and forecast, by Distribution Channel

6.4.4.3 India

6.4.4.3.1 Key market trends, growth factors and opportunities

6.4.4.3.2 Market size and forecast, by Drug Type

6.4.4.3.3 Market size and forecast, by Distribution Channel

6.4.4.4 South Korea

6.4.4.4.1 Key market trends, growth factors and opportunities

6.4.4.4.2 Market size and forecast, by Drug Type

6.4.4.4.3 Market size and forecast, by Distribution Channel

6.4.4.5 Australia

6.4.4.5.1 Key market trends, growth factors and opportunities

6.4.4.5.2 Market size and forecast, by Drug Type

6.4.4.5.3 Market size and forecast, by Distribution Channel

6.4.4.6 Rest of Asia-Pacific

6.4.4.6.1 Key market trends, growth factors and opportunities

6.4.4.6.2 Market size and forecast, by Drug Type

6.4.4.6.3 Market size and forecast, by Distribution Channel

6.5 LAMEA

6.5.1 Key trends and opportunities

6.5.2 LAMEA Market size and forecast, by Drug Type

6.5.3 LAMEA Market size and forecast, by Distribution Channel

6.5.4 LAMEA Market size and forecast, by country

6.5.4.1 Brazil

6.5.4.1.1 Key market trends, growth factors and opportunities

6.5.4.1.2 Market size and forecast, by Drug Type

6.5.4.1.3 Market size and forecast, by Distribution Channel

6.5.4.2 Saudi Arabia

6.5.4.2.1 Key market trends, growth factors and opportunities

6.5.4.2.2 Market size and forecast, by Drug Type

6.5.4.2.3 Market size and forecast, by Distribution Channel

6.5.4.3 South Africa

6.5.4.3.1 Key market trends, growth factors and opportunities

6.5.4.3.2 Market size and forecast, by Drug Type

6.5.4.3.3 Market size and forecast, by Distribution Channel

6.5.4.4 Rest of LAMEA

6.5.4.4.1 Key market trends, growth factors and opportunities

6.5.4.4.2 Market size and forecast, by Drug Type

6.5.4.4.3 Market size and forecast, by Distribution Channel

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.5. Top player positioning, 2021

8.1 Apotex

8.1.1 Company overview

8.1.2 Key Executives

8.1.3 Company snapshot

8.1.4 Operating business segments

8.1.5 Product portfolio

8.1.6 Business performance

8.1.7 Key strategic moves and developments

8.2 ANI Pharmaceuticals Inc

8.2.1 Company overview

8.2.2 Key Executives

8.2.3 Company snapshot

8.2.4 Operating business segments

8.2.5 Product portfolio

8.2.6 Business performance

8.2.7 Key strategic moves and developments

8.3 Teva Pharmaceutical Industries Limited

8.3.1 Company overview

8.3.2 Key Executives

8.3.3 Company snapshot

8.3.4 Operating business segments

8.3.5 Product portfolio

8.3.6 Business performance

8.3.7 Key strategic moves and developments

8.4 Lupin Ltd

8.4.1 Company overview

8.4.2 Key Executives

8.4.3 Company snapshot

8.4.4 Operating business segments

8.4.5 Product portfolio

8.4.6 Business performance

8.4.7 Key strategic moves and developments

8.5 Dr.Reddy's Laboratories Ltd

8.5.1 Company overview

8.5.2 Key Executives

8.5.3 Company snapshot

8.5.4 Operating business segments

8.5.5 Product portfolio

8.5.6 Business performance

8.5.7 Key strategic moves and developments

8.6 Bausch Health Companies Inc.

8.6.1 Company overview

8.6.2 Key Executives

8.6.3 Company snapshot

8.6.4 Operating business segments

8.6.5 Product portfolio

8.6.6 Business performance

8.6.7 Key strategic moves and developments

8.7 Panacea Biotec Ltd

8.7.1 Company overview

8.7.2 Key Executives

8.7.3 Company snapshot

8.7.4 Operating business segments

8.7.5 Product portfolio

8.7.6 Business performance

8.7.7 Key strategic moves and developments

8.8 par pharmaceutical

8.8.1 Company overview

8.8.2 Key Executives

8.8.3 Company snapshot

8.8.4 Operating business segments

8.8.5 Product portfolio

8.8.6 Business performance

8.8.7 Key strategic moves and developments

8.9 navinta llc

8.9.1 Company overview

8.9.2 Key Executives

8.9.3 Company snapshot

8.9.4 Operating business segments

8.9.5 Product portfolio

8.9.6 Business performance

8.9.7 Key strategic moves and developments

8.10 breckenridge pharmaceutical, inc.

8.10.1 Company overview

8.10.2 Key Executives

8.10.3 Company snapshot

8.10.4 Operating business segments

8.10.5 Product portfolio

8.10.6 Business performance

8.10.7 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 2. WILSON DISEASE DRUGS MARKET FOR PENICILLAMINE, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. WILSON DISEASE DRUGS MARKET FOR TRIENTINE, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 4. WILSON DISEASE DRUGS MARKET FOR ZINC, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. GLOBAL WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 6. WILSON DISEASE DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 7. WILSON DISEASE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 8. WILSON DISEASE DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 9. WILSON DISEASE DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 10. NORTH AMERICA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 11. NORTH AMERICA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 12. NORTH AMERICA WILSON DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 13. U.S. WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 14. U.S. WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 15. CANADA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 16. CANADA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 17. MEXICO WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 18. MEXICO WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 19. EUROPE WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 20. EUROPE WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 21. EUROPE WILSON DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 22. GERMANY WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 23. GERMANY WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 24. FRANCE WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 25. FRANCE WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 26. UK WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 27. UK WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 28. ITALY WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 29. ITALY WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 30. SPAIN WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 31. SPAIN WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 32. REST OF EUROPE WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 33. REST OF EUROPE WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 34. ASIA-PACIFIC WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 35. ASIA-PACIFIC WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 36. ASIA-PACIFIC WILSON DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 37. CHINA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 38. CHINA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 39. JAPAN WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 40. JAPAN WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 41. INDIA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 42. INDIA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 43. SOUTH KOREA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 44. SOUTH KOREA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 45. AUSTRALIA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 46. AUSTRALIA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 47. REST OF ASIA-PACIFIC WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 48. REST OF ASIA-PACIFIC WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 49. LAMEA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 50. LAMEA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 51. LAMEA WILSON DISEASE DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 52. BRAZIL WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 53. BRAZIL WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 54. SAUDI ARABIA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 55. SAUDI ARABIA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 56. SOUTH AFRICA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 57. SOUTH AFRICA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 58. REST OF LAMEA WILSON DISEASE DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 59. REST OF LAMEA WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)

TABLE 60.APOTEX: KEY EXECUTIVES

TABLE 60.APOTEX: COMPANY SNAPSHOT

TABLE 61.APOTEX: OPERATING SEGMENTS

TABLE 62.APOTEX: PRODUCT PORTFOLIO

TABLE 63.APOTEX: NET SALES

TABLE 64.APOTEX: KEY STRATERGIES

TABLE 66.ANI PHARMACEUTICALS INC: KEY EXECUTIVES

TABLE 66.ANI PHARMACEUTICALS INC: COMPANY SNAPSHOT

TABLE 67.ANI PHARMACEUTICALS INC: OPERATING SEGMENTS

TABLE 68.ANI PHARMACEUTICALS INC: PRODUCT PORTFOLIO

TABLE 69.ANI PHARMACEUTICALS INC: NET SALES

TABLE 70.ANI PHARMACEUTICALS INC: KEY STRATERGIES

TABLE 72.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES

TABLE 72.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 73.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING SEGMENTS

TABLE 74.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 75.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES

TABLE 76.TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGIES

TABLE 78.LUPIN LTD: KEY EXECUTIVES

TABLE 78.LUPIN LTD: COMPANY SNAPSHOT

TABLE 79.LUPIN LTD: OPERATING SEGMENTS

TABLE 80.LUPIN LTD: PRODUCT PORTFOLIO

TABLE 81.LUPIN LTD: NET SALES

TABLE 82.LUPIN LTD: KEY STRATERGIES

TABLE 84.DR.REDDY'S LABORATORIES LTD: KEY EXECUTIVES

TABLE 84.DR.REDDY'S LABORATORIES LTD: COMPANY SNAPSHOT

TABLE 85.DR.REDDY'S LABORATORIES LTD: OPERATING SEGMENTS

TABLE 86.DR.REDDY'S LABORATORIES LTD: PRODUCT PORTFOLIO

TABLE 87.DR.REDDY'S LABORATORIES LTD: NET SALES

TABLE 88.DR.REDDY'S LABORATORIES LTD: KEY STRATERGIES

TABLE 90.BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES

TABLE 90.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT

TABLE 91.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS

TABLE 92.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO

TABLE 93.BAUSCH HEALTH COMPANIES INC.: NET SALES

TABLE 94.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES

TABLE 96.PANACEA BIOTEC LTD: KEY EXECUTIVES

TABLE 96.PANACEA BIOTEC LTD: COMPANY SNAPSHOT

TABLE 97.PANACEA BIOTEC LTD: OPERATING SEGMENTS

TABLE 98.PANACEA BIOTEC LTD: PRODUCT PORTFOLIO

TABLE 99.PANACEA BIOTEC LTD: NET SALES

TABLE 100.PANACEA BIOTEC LTD: KEY STRATERGIES

TABLE 102.PAR PHARMACEUTICAL: KEY EXECUTIVES

TABLE 102.PAR PHARMACEUTICAL: COMPANY SNAPSHOT

TABLE 103.PAR PHARMACEUTICAL: OPERATING SEGMENTS

TABLE 104.PAR PHARMACEUTICAL: PRODUCT PORTFOLIO

TABLE 105.PAR PHARMACEUTICAL: NET SALES

TABLE 106.PAR PHARMACEUTICAL: KEY STRATERGIES

TABLE 108.NAVINTA LLC: KEY EXECUTIVES

TABLE 108.NAVINTA LLC: COMPANY SNAPSHOT

TABLE 109.NAVINTA LLC: OPERATING SEGMENTS

TABLE 110.NAVINTA LLC: PRODUCT PORTFOLIO

TABLE 111.NAVINTA LLC: NET SALES

TABLE 112.NAVINTA LLC: KEY STRATERGIES

TABLE 114.BRECKENRIDGE PHARMACEUTICAL, INC.: KEY EXECUTIVES

TABLE 114.BRECKENRIDGE PHARMACEUTICAL, INC.: COMPANY SNAPSHOT

TABLE 115.BRECKENRIDGE PHARMACEUTICAL, INC.: OPERATING SEGMENTS

TABLE 116.BRECKENRIDGE PHARMACEUTICAL, INC.: PRODUCT PORTFOLIO

TABLE 117.BRECKENRIDGE PHARMACEUTICAL, INC.: NET SALES

TABLE 118.BRECKENRIDGE PHARMACEUTICAL, INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1. SEGMENTATION OF WILSON DISEASE DRUGS MARKET,2021-2031

FIGURE 2.WILSON DISEASE DRUGS MARKET,2021-2031

FIGURE 3. TOP INVESTMENT POCKETS, BY REGION

FIGURE 4.PORTER FIVE-1

FIGURE 5.PORTER FIVE-2

FIGURE 6.PORTER FIVE-3

FIGURE 7.PORTER FIVE-4

FIGURE 8.PORTER FIVE-5

FIGURE 9.WILSON DISEASE DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10.WILSON DISEASE DRUGS MARKET,BY DRUG TYPE,2021(%)

FIGURE 11.COMPARATIVE SHARE ANALYSIS OF PENICILLAMINE WILSON DISEASE DRUGS MARKET, 2021 AND 2031(%)

FIGURE 12.COMPARATIVE SHARE ANALYSIS OF TRIENTINE WILSON DISEASE DRUGS MARKET, 2021 AND 2031(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ZINC WILSON DISEASE DRUGS MARKET, 2021 AND 2031(%)

FIGURE 14.WILSON DISEASE DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)

FIGURE 15.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES WILSON DISEASE DRUGS MARKET, 2021 AND 2031(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES WILSON DISEASE DRUGS MARKET, 2021 AND 2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES WILSON DISEASE DRUGS MARKET, 2021 AND 2031(%)

FIGURE 18.WILSON DISEASE DRUGS MARKET BY REGION,2021

FIGURE 19.U.S. WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 20.CANADA WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 21.MEXICO WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 22.GERMANY WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 23.FRANCE WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 24.UK WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 25.ITALY WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 26.SPAIN WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 27.REST OF EUROPE WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 28.CHINA WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 29.JAPAN WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 30.INDIA WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 31.SOUTH KOREA WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 32.AUSTRALIA WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 33.REST OF ASIA-PACIFIC WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 34.BRAZIL WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 35.SAUDI ARABIA WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 36.SOUTH AFRICA WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 37.REST OF LAMEA WILSON DISEASE DRUGS MARKET,2021-2031($MILLION)

FIGURE 38. TOP WINNING STRATEGIES, BY YEAR

FIGURE 39. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 40. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 41.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 42.COMPETITIVE DASHBOARD

FIGURE 43.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 44.TOP PLAYER POSITIONING, 2021

FIGURE 45.APOTEX.: NET SALES ($MILLION)

FIGURE 46.ANI PHARMACEUTICALS INC.: NET SALES ($MILLION)

FIGURE 47.TEVA PHARMACEUTICAL INDUSTRIES LIMITED.: NET SALES ($MILLION)

FIGURE 48.LUPIN LTD.: NET SALES ($MILLION)

FIGURE 49.DR.REDDY'S LABORATORIES LTD.: NET SALES ($MILLION)

FIGURE 50.BAUSCH HEALTH COMPANIES INC..: NET SALES ($MILLION)

FIGURE 51.PANACEA BIOTEC LTD.: NET SALES ($MILLION)

FIGURE 52.PAR PHARMACEUTICAL.: NET SALES ($MILLION)

FIGURE 53.NAVINTA LLC.: NET SALES ($MILLION)

FIGURE 54.BRECKENRIDGE PHARMACEUTICAL, INC..: NET SALES ($MILLION